Altogether, the presented data suggest PCI of MH3-B1/rGel as a HER2-targeted treatment approach for HER2-positive cancers, including ovarian cancers resistant to HER2-targeted therapeutics. The gene discussed is ERBB2; the disease is ovarian cancer.